Throughout the study timeframe, 961 participants using GLP-1RAs developed depression, and 902 participants using SGLT2is developed depression
Liraglutide persistence data further illustrate this challenge real-world studies indicate an average treatment duration of only 6.3 months, suggesting most patients discontinue before reaching the conventional 6-month assessment point typically used in clinical guidelines
Inhibition of cell growth by overexpression of manganese superoxide dismutase (MnSOD) in human pancreatic carcinoma
New startup to develop a GLP-1 drug for addiction A company called Baseline Therapeutics launched today with a focus on studying a GLP-1 drug for various substance use disorders
If your plan doesnt cover Rybelsus but does cover a different GLP-1, it may be worth exploring alternatives
IPAMORELIN THERAPY OPTION Ipamorelin is a pentapeptide comprised of amino acids and acts as a GHRP (Growth Hormone Releasing Peptide) In contrast to our typical GHRPs used with Sermorelin, Ipamorelin does not significantly boost, cortisol, aldosterone, or acetylcholine levels